KA Imaging’s X-ray Detector Allows Dual Energy to Be Taken to the Bedside

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

July 9, 2020

KA Imaging notes: For the first time, practitioners will be able to leverage dual-energy x-ray technology in a portable system. Canadian manufacturer KA Imaging is getting ready to launch Reveal, the world’s first dual-energy x-ray detector that can be taken to the bedside.

KA Imaging President and CEO Amol Karnick notes, “Due to the infectious nature of COVID-19, bringing patients into a fixed radiology room can sometimes be risky.” He added, “Current dual-energy systems are all fixed and Reveal overcomes the limitation of a fixed room by providing a world-first portable dual-energy solution. Reveal provides radiologists with an unobstructed view of the lungs by removing the bones in an x-ray image.”

The FDA 510(k) pending detector works with a single exposure. Unlike fixed dual-energy solutions, Reveal’s technology enables bone and soft tissue differentiation with no motion artifact. “Our patented technology also allows lateral and oblique dual-energy views for the first time”, explains Dr. Karim S Karim, CTO at KA Imaging.

Whereas fixed dual-energy systems can cost as high as half a million dollars, KA Imaging’s Reveal is highly affordable at less than ¼ of this price.

“If a hospital requires dual-energy X-ray for COVID-19, you can simply replace any older CR plate or digital fixed or portable detector with Reveal”, says Amol.

Clinical trials

The company is planning clinical trials globally to demonstrate the efficacy of Reveal in triaging COVID-19 and other imaging tasks in the Emergency Room and Intensive Care Units. One of them is expected to begin in Toronto by August. “The world needs affordable and effective portable bedside diagnostics now, and Reveal is a solution that can provide tremendous value for clinicians, hospitals and government”, emphasizes Karim.

Reveal is also being tested on patients with lung cancer. Grand River Hospital (Kitchener, Ontario, Canada) was the first to test the technology. More than 20 patients have been imaged with Reveal, with promising initial results.

ECR

Radiologists globally can learn more about Reveal at the European Congress of Radiology (ECR) from July 15th to 19th. Due to the pandemic, the conference will be held online. KA Imaging is part of the virtual exhibition.

spot_img

DON'T MISS

Related Articles